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Abstract
Context: There have been few longitudinal studies of cytokine production in neonatally acquired
HIV-1 infection and none in Asian or Chinese children.
Objective: To determine whether monitoring cytokine production could contribute to the better
management of pediatric patients with HIV-1 infection.
Setting: Clinical Immunology Laboratory and Pediatrics Department, University Hospital, Hong
Kong.
Patients: Ten Asian and 2 Eurasian children infected with HIV-1 by mother-to-child transmission
were followed for up to 5 years while on treatment with highly active antiretroviral therapy
(HAART).
Main Outcome Measures: Numbers of unstimulated and mitogen-activated cytokine-secreting
cells (IFN-gamma, interleukin [IL]-2, IL-4, IL-6, IL-10, IL-12, and TNF-alpha) were measured by
ELISPOT assay at frequent intervals, and correlations were sought with CD4+ and CD8+ cell
counts and viral loads.
Results: Mitogen-stimulated IL-2-secreting cells were directly associated with recovery of CD4+
cells. Correlations with viral load were found for Con A-induced IFN-gamma, Con A-induced IL-4,
and unstimulated IL-10, suggesting that these cytokines were either suppressed by high virus levels
or that higher cytokine levels suppressed virus. IFN-gamma, IL-2-, IL-4-, and IL-12-secreting cells
induced by PHA, Con A, and/or SAC tended to increase for the first 34 years of treatment but
declined thereafter.
Conclusion: Alterations in cytokine profiles were not associated with adverse clinical events and
there was little evidence to indicate that monitoring cytokine enzyme-linked immunospots
(ELISPOTs) could contribute to pediatric patient management.
Published: 3 May 2005
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Introduction
With the advent of highly active antiretroviral therapy
(HAART), human immunodeficiency virus type 1 (HIV-1)
can be controlled for prolonged periods,[1] although the
virus cannot be eliminated[2] and treatment failures occur
due to development of drug-resistant mutations.[3]
Chronic immune hyperactivation and raised T-cell turno-
ver due to continued viral replication and antigenic stim-
ulation are present even after HAART has decreased the
viral load to undetectable levels.[4]
Both proinflammatory and regulatory cytokines are pro-
duced during chronic immune stimulation. Proinflamma-
tory cytokines, such as interleukin (IL)-1, IL-6, and tumor
necrosis factor-alpha (TNF-alpha), contribute to tissue
pathology, especially in the brain,[5] and can induce tran-
scription of latent HIV-1.[6,7] Type 2 or regulatory
cytokines, such as IL-4, IL-6, and IL-10, can suppress type
1 cytokines and induce polyclonal B-cell activation,[8]
lymphomagenesis,[9] autoantibody production,[10] and
manifestations of allergy.[11] Type 1 cytokines, such as IL-
12, interferon (IFN) gamma, and IL-2, are important for
antiviral cell-mediated immunity.[12] During the long
course of HIV-1 infection, type 2 cytokines gradually
come to predominate over type 1 cytokines,[13-16]
although this finding is not universally accepted.[17]
There have been few studies of in vitro cytokine produc-
tion in neonatally acquired HIV-1 infection in Asian or
Chinese children. The enzyme-linked immunospot (ELIS-
POT) system for measuring unstimulated or mitogen-acti-
vated cytokine secreting cells has not been evaluated in
this context. We wished to know whether monitoring
cytokine production in addition to CD4+ cell counts and
viral load could provide additional useful information in
pediatric patients with HIV-1 infection being treated with
HAART. We hoped to identify cytokine profiles that are
characteristic of either clinical improvement or disease
progression, so that manipulation towards the desirable
profile might be attempted.
Materials and methods
Patients
This study was approved by the Institutional Review
Board of Hong Kong West Hospital Cluster and The Uni-
versity of Hong Kong, and informed consent was obtained
from the parents of all subjects. Clinical findings in 8 of
the patients have been described previously.[18] Ten
Asian and 2 Eurasian children, 4 girls and 8 boys, were
infected by mother-to-child-transmission of HIV-1. They
were initially diagnosed between 1996 and 2002 at age
364 (median, 32) months and they have been followed
for 961 (median, 44) months (Table). At the time of diag-
nosis, 9 children had low CD4+ cell counts (compared
with the age-specific normal range[19]) and the median
plasma HIV-1 RNA level was 500,000 copies/mL
(110,0001,300,000). All children had lymphadenopathy
and/or hepatosplenomegaly at diagnosis. One girl
(patient 3) developed NKT-cell lymphoma which caused
her death, the only fatality during the study period. Most
of the patients had infectious complications, including
Pneumocystis carinii pneumonia (1), viral pneumonia (1),
disseminated Penicillium marneffei (1), thrush (4), tinea
capitis (1), and herpes simplex (1). Other complications
included neutropenia in 1 patient, hepatitis and anemia
in 1, and asthma and/or rhinitis in 3. Patients were started
on HAART immediately after confirmation of HIV-1 infec-
tion and were treated with 2 nucleoside reverse tran-
scriptase inhibitors (zidovudine, lamivudine, didanosine,
stavudine, and/or abacavir) plus 1 protease inhibitor
(indinavir, nelfinavir, Kaletra  (lopinavir + ritonavir),
ritonavir, or amprenavir) or the nonnucleoside reverse
transcriptase inhibitor nevirapine. Details are given in the
Table. Patients were examined and blood for hemato-
logic, virologic, and immunologic evaluation was taken
every 26 months. The first cytokine evaluation was per-
formed within 1 month of starting HAART in 7 patients,
within 24 months in 3 patients, and after 16 and 19
months in 2 patients.
ELISPOT Assay
Numbers of cytokine-secreting cells in unstimulated cul-
tures or cultures stimulated with T-cell activators phytohe-
magglutinin (PHA), Concanavalin A (Con A), or
monocyte activator Staphylococcus aureus Cowan I (SAC)
were determined using ELISPOT assays.[20,21] Details of
our adaptation of this method and its specificity and
reproducibility (intra- and interassay CVs 8.8 ± 5.8% and
13.2 ± 4.9%, respectively) have been reported.[22-26]
Results for normal controls evaluated over the study
period remained stable within our established reference
ranges.
Briefly, peripheral blood mononuclear cells (PBMCs)
were separated over Lymphoprep  (Nycomed; Oslo, Nor-
way) within 1 hour of blood collection and added to 96-
well Multiscreen plates (Millipore; Bedford, Massachusetts,
USA) which had previously been coated overnight at 4°C
with cytokine capture antibodies (Pharmingen; San
Diego, California, USA) at 2 (IL-4, IL-6, IL-10), 4 (IL-12,
TNF-alpha), or 8 (IFN-gamma, IL-2) mcg/mL in 0.1 M
NaHCO3, pH 8.2, and blocked with 5% fetal calf serum
(FCS) in culture medium RPMI 1640 for at least 1 hour at
37°C. Duplicate cultures of 104 (for IL-6 and TNF-alpha)
or 105 (for IFN-gamma, IL-2, IL-4, IL-10, and IL-12) viable
cells/well in RPMI + 5% FCS with or without PHA at a
final concentration of 10 mcg/mL, Con A at 20 mcg/mL,
or SAC at 0.001% v/v were incubated for 22 hours at 37°C
in 5% CO2. Cells were then washed out with 0.01 M phos-
phate-buffered saline containing 0.05% Tween 20 (PBS-Journal of the International AIDS Society 2005, 7:71 http://www.jiasociety.org/content/7/2/71
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T) and plates incubated sequentially with biotinylated
detection anti-cytokine antibodies (Pharmingen), 0.5
mcg/mL in PBS-T for 90 minutes, streptavidin-alkaline
phosphatase (Sigma; St. Louis, Missouri, USA), 1/400 v/v
in PBS-T for 60 minutes and 5-bromo-4-chloro-3-indolyl-
phosphate-nitroblue tetrazolium (Calbiochem; La Jolla,
California, USA) for 20 minutes, all at room temperature.
Plates were washed extensively with PBS-T between each
incubation and with saline to remove phosphate prior to
addition of phosphatase substrate. Color development
was stopped and pathogens inactivated by immersion in
2% Clorox bleach followed by rinsing under the tap and
allowing plates to dry for 1 hour. Blue spots correspond-
ing to each cytokine-secreting cell were counted by micro-
scopy and results expressed as ELISPOTs/106 PBMCs.
Flow Cytometry
CD3+4+ T-helper cells and CD3+8+ T-cytotoxic cells were
enumerated using commercial monoclonal antibodies
(Beckman Coulter; Miami, Florida, USA) by dual color
flow cytometry (EPICS XL-MCL, Coulter). White cell and
differential counts were performed by standard methods.
Virus Load Measurement
HIV-1 RNA quantitation was by Amplicor HIV-1 Monitor
(Roche Diagnostics Corporation; Branchburg, New Jersey,
USA). The standard method, performed according to the
manufacturer's recommendations, has a measuring range
of 400750,000 RNA copies/mL.
Statistical Analysis
Correlations between numbers of cytokine-secreting cells
and proportions and absolute numbers of CD4+ and
CD8+ cells, CD4:CD8 ratios, and virus load were evalu-
ated by multiple regression analysis, with or without log-
arithmic transformation, and linear regression lines were
plotted. Parametric rather than nonparametric statistics
were used, despite small numbers of patients, because we
wished to derive formulae for estimation of cytokine lev-
els predictive of viral load or lymphocyte subset count.
Log transformation was performed for viral load data
because skewness and kurtosis of raw data were 3.7 and
12.8, respectively; these became 1.2 and 0.5, respectively,
after log transformation. Curves of numbers of cytokine-
secreting cells plotted against length of treatment with
HAART were fitted by nonlinear regression. The statistical
software used was GraphPad Prism Version 4.00 for Win-
dows (GraphPad Software; San Diego, California, USA,
www.graphpad.com).
Results
Twelve Asian or Eurasian children infected with HIV-1 by
mother-to-child transmission were treated with HAART
from the time of diagnosis. They were 360 (median, 25)
months old when initially diagnosed and were therefore
heterogeneous with regard to immunologic maturity,
duration of infection with HIV-1, and extent of immuno-
deficiency due to HIV-1. They all had high viral loads and
most had low CD4+ cell counts when diagnosed and
entered into the study. One child died of lymphoma at
age 29 months after she had received HAART for 9
months, during which time her CD4+ cells increased and
the viral load decreased to undetectable. At the end of the
study, the 11 surviving patients were well and thriving.
Seven had normal or higher-than-normal circulating
CD4+ cells/mcL, but 4 patients still had reduced numbers
and/or percentages. Plasma HIV-1 RNA was consistently
below the level of detection in all but 1 of the surviving
children when the study closed. Undetectable plasma
Multiple regression correlation of numbers of IL-2-secreting cells/106 PBMCs with CD4+ and CD8+ T-cell counts in 12 pedi- atric patients treated with HAART Figure 1
Multiple regression correlation of numbers of IL-2-secreting cells/106 PBMCs with CD4+ and CD8+ T-cell 
counts in 12 pediatric patients treated with HAART. (A) IL-2 PHA vs CD4%, P = .0149; (B) IL-2 Con A vs CD4%, P = 
.0109
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HIV-1 RNA was achieved in 255 months (median, 9.5
months).
For each cytokine and culture condition studied while
patients were receiving HAART, 112 corresponding values
of CD4+ and CD8+ cells and 96 corresponding values of
plasma HIV-1 RNA copies/mL were available. All of these
data were used to examine whether cytokine production
correlated with disease progression.
IFN-gamma, IL-2, and IL-4 ELISPOTs were undetectable
in unstimulated PBMCs, as reported previously.[22-26]
Numbers of PHA- or Con A-stimulated IL-2-secreting cells
increased during recovery from CD4 deficiency and corre-
lated directly with CD4 and CD8 absolute counts, CD4
percentages, and CD4:CD8 ratios and inversely with CD8
percentages by multiple regression analysis. The data
could be described by the following equations: CD4% =
0.00234 (IL-2 PHA) + 0.00355 (IL-2 Con A) + 17.47;
CD4/mcL = 0.3852 (IL-2 PHA) + 1084.8; CD8% =
40.650.0025 (IL-2 Con A); CD8/mcL = 0.2083 (IL-2 PHA)
+ 1211.9; CD4:CD8 = 0.00018 (IL-2 Con A) + 0.478. IFN-
gamma, IL-4, IL-6, IL-10, IL-12, and TNF-alpha-secreting
cells induced under any of the culture conditions
employed did not correlate with T-cell subsets. See Figures
1, 2 and 3.
There were no significant correlations of cytokine-produc-
ing cells with virus load by multiple regression analysis of
untransformed data, but log-transformed Con A-induced
Multiple regression correlation of numbers of IL-2-secreting cells/106 PBMCs with CD4+ and CD8+ T-cell counts in 12 pedi- atric patients treated with HAART Figure 3
Multiple regression correlation of numbers of IL-2-secreting cells/106 PBMCs with CD4+ and CD8+ T-cell 
counts in 12 pediatric patients treated with HAART. (E) IL-2 PHA vs CD8/mcL, P = .0008; (F) IL-2 Con A vs CD4:CD8, 
P = .0035
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Multiple regression correlation of numbers of IL-2-secreting cells/106 PBMCs with CD4+ and CD8+ T-cell counts in 12 pedi- atric patients treated with HAART Figure 2
Multiple regression correlation of numbers of IL-2-secreting cells/106 PBMCs with CD4+ and CD8+ T-cell 
counts in 12 pediatric patients treated with HAART. (C) IL-2 PHA vs CD4/mcL, P = .0008; (D) IL-2 Con A vs CD8%, P 
= .0196
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IFN-gamma-, Con A-induced IL-4- and unstimulated IL-
10-secreting cells increased significantly as virus load fell
(Figure 4). The data were described by the following equa-
tion: log10 viral load = 7.4530.6207 (log10 IL-4 Con A)
0.9504 (log10 IL-4 Con A) + 0.5434 (log10 IL-10 unstimu-
lated).
All of the data from ELISPOT assays were plotted against
duration of HAART. Numbers of IFN-gamma, IL-2, IL-4,
and IL-12-secreting cells tended to increase for the first 34
years of treatment but declined thereafter. Changes in IL-
6, IL-10, and TNF-alpha-secreting cells over time were less
apparent. See Figures 5, 6, 7, 8 and figures 9, 10 and 11.
Discussion
The effect of HIV-1 on maturation of the immune system
in general and of cytokine production in particular is not
well understood, especially in the context of treatment
with HAART. We wished to know whether regular moni-
toring of mitogen-induced cytokine production in addi-
tion to CD4+ cell counts and virus load would be a valid
measure of immunologic competence and therefore a use-
ful additional parameter for clinical monitoring. We also
looked for correlations between cytokine production,
viral load, and CD4+ cell numbers in the hope of identi-
fying cytokine profiles associated with favorable outcome.
However, we were limited to only 12 HIV-infected chil-
dren available for study in Hong Kong, and statistical bias
could have occurred due to heterogeneity with regard to
immunologic maturity at the time of diagnosis, duration
of infection with HIV-1, and extent of immunodeficiency
when starting HAART.
IL-2 was the only cytokine of those studied that correlated
positively with increasing CD4+ T-cell percentage and
absolute number and increasing CD4:CD8 ratios. Treat-
ment with exogenous IL-2 has been shown to increase
peripheral expansion of CD4+ cells.[27] IL-2 production
also correlated with CD8+ T-cell increases but, surpris-
ingly, because this population includes the major cyto-
toxic effector cells against HIV, it did not correlate with
viral load.
HIV-1 RNA copies/mL correlated inversely with Con A-
induced IFN-gamma, Con A-induced IL-4, and unstimu-
lated IL-10, suggesting that these cytokines might be
involved in the control of HIV-1 levels. It is impossible to
distinguish between the possibility that high levels of
virus suppressed production of these cytokines and/or
that virus survived better when production of these
cytokines was limited. In contrast to our findings, a previ-
ous study reported that plasma IL-10 declined during ade-
quate virologic and immunologic responses in HAART-
treated adults.[28] Differences in race and age of patients
in the 2 studies may have contributed to these conflicting
findings. Also in contrast to our study, IFN-
gamma[29]and TNF-alpha[29,30] declined during ade-
quate virologic and immunologic responses in HAART-
treated adults. However, Reuben and colleagues[31]
found increased plasma IFN-gamma after virus suppres-
sion in pediatric patients and Resino and coworkers[32]
found lower PHA-induced TNF-alpha and IFN-gamma in
Multiple regression correlations of virus load with numbers  of (A) Con A-induced IFN-gamma-secreting cells/106  PBMCs, P = .0231; (B) Con A-induced IL-4-secreting cells/ 106 PBMCs, P = .0294; (C) unstimulated IL-10-secreting  cells/106 PBMCs, P = .0015 Figure 4
Multiple regression correlations of virus load with 
numbers of (A) Con A-induced IFN-gamma-secret-
ing cells/106 PBMCs, P = .0231; (B) Con A-induced 
IL-4-secreting cells/106 PBMCs, P = .0294; (C) 
unstimulated IL-10-secreting cells/106 PBMCs, P = 
.0015. The data were log-transformed.
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Numbers of IFN-gamma, IL-2, IL-4, and IL-12-secreting cells in 12 pediatric patients treated with HAART. Cytokine-secreting  cells tended to increase for the first 34 years of treatment but declined thereafter Figure 7
Numbers of IFN-gamma, IL-2, IL-4, and IL-12-secreting cells in 12 pediatric patients treated with HAART. 
Cytokine-secreting cells tended to increase for the first 34 years of treatment but declined thereafter. Curves were fitted by 
nonlinear regression.
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Numbers of IFN-gamma, IL-2, IL-4, and IL-12-secreting cells in 12 pediatric patients treated with HAART. Cytokine-secreting  cells tended to increase for the first 34 years of treatment but declined thereafter Figure 5
Numbers of IFN-gamma, IL-2, IL-4, and IL-12-secreting cells in 12 pediatric patients treated with HAART. 
Cytokine-secreting cells tended to increase for the first 34 years of treatment but declined thereafter. Curves were fitted by 
nonlinear regression.
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Numbers of IFN-gamma, IL-2, IL-4, and IL-12-secreting cells in 12 pediatric patients treated with HAART. Cytokine-secreting  cells tended to increase for the first 34 years of treatment but declined thereafter Figure 6
Numbers of IFN-gamma, IL-2, IL-4, and IL-12-secreting cells in 12 pediatric patients treated with HAART. 
Cytokine-secreting cells tended to increase for the first 34 years of treatment but declined thereafter. Curves were fitted by 
nonlinear regression.
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Numbers of IL-6, IL-10, and TNF-alpha-secreting cells in 12 pediatric patients treated with HAART Figure 9
Numbers of IL-6, IL-10, and TNF-alpha-secreting cells in 12 pediatric patients treated with HAART. Cytokine-
secreting cells tended to remain stable over the study period. Curves were fitted by nonlinear regression.
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Numbers of IFN-gamma, IL-2, IL-4, and IL-12-secreting cells in 12 pediatric patients treated with HAART. Cytokine-secreting  cells tended to increase for the first 34 years of treatment but declined thereafter Figure 8
Numbers of IFN-gamma, IL-2, IL-4, and IL-12-secreting cells in 12 pediatric patients treated with HAART. 
Cytokine-secreting cells tended to increase for the first 34 years of treatment but declined thereafter. Curves were fitted by 
nonlinear regression.
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Numbers of IL-6, IL-10, and TNF-alpha-secreting cells in 12 pediatric patients treated with HAART Figure 10
Numbers of IL-6, IL-10, and TNF-alpha-secreting cells in 12 pediatric patients treated with HAART. Cytokine-
secreting cells tended to remain stable over the study period. Curves were fitted by nonlinear regression.
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rapid-progressor children than in those who were long-
term asymptomatic. It is therefore possible that these
cytokines may interact differently with HIV in children
and adults. It should also be borne in mind that enumer-
ation of cytokine-secreting cells following in vitro
mitogen stimulation of isolated PBMCs is unlikely to
compare directly with cytokine quantitation in plasma.
Our novel finding that Con A-induced IL-4 was negatively
correlated with viral load is in line with its ability to
inhibit phorbol ester-stimulated HIV-1 expression in
chronically infected promonocytic U1 cells.[33] The effect
of IL-4 on HIV in culture merits further study.
We did not observe changes over time that suggested that
type 2 cytokine production was tending to predominate
over type 1 cytokines, as was described in some[13-16]
but not all[17] reports. Instead we observed that the pre-
sumably desirable increase in numbers of both type 1
(IFN-gamma, IL-2, and IL-12) and type 2 (IL-4) ELIS-
POTs/106 PBMCs during the first 34 years of treatment
with HAART was not maintained beyond this time (Figure
3). It is not known whether a reducing trend of this nature
presages failing immune protection or, more hopefully,
lessening of HIV-1-induced immune hyperactivation.
Continued observation of this small cohort of patients
should allow us to determine whether these changes in
cytokine production are related to the eventual clinical
outcome.
The ELISPOT assay used in this investigation has been
optimized for reproducibility and sensitivity. It does not
require specialized equipment and is relatively easy to
perform and inexpensive (approximately US$32 per
patient for 7 cytokines and the different activating condi-
tions). We have previously used this system to investigate
in vitro cytokine production in a number of clinical situa-
tions.[22-26] The assay performed favorably when data
from groups of patients were pooled for statistical com-
parison, but there was wide variation in values for differ-
ent subjects and day-to-day variability due to factors such
as subclinical illness, mild tissue injury, and possibly var-
iable stress levels. It was not ethically feasible to have
either a healthy matched pediatric control group or an
untreated pediatric HIV control group in the present
study, so we were limited to a comparison of cytokine pro-
files in individual patients at times of relatively good and
poor health and of improving or worsening CD4+ cell
counts or viral loads. We were unable to identify cytokine
profiles that were associated with or predictive of HIV-
related clinical events. Cytokine profiling using mitogen-
stimulated ELISPOT assays is therefore unlikely to be an
important clinical measure that could influence or
improve the accuracy of patient management decisions.
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